Information letter to healthcare professionals on the safe use of the medicinal product BINFIN. Medicinal products containing finasteride (finasteride) and dutasteride (dutasteride): new measures to minimize the risk of suicidal thoughts

29.04.2026 Updated 04.05.2026 342 views

Information letter to healthcare professionals regarding the safety of use of the medicinal product BINFIN. Medicinal products containing finasteride and dutasteride: new measures to minimize the risk of suicidal thoughtsPDF · 137 KB

Завантажити

Information letter to healthcare professionals on the safe use of the medicinal product BINFIN. Medicinal products containing finasteride (finasteride) and dutasteride (dutasteride): new measures to minimize the risk of suicidal thoughts

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals on the safe use of the medicinal product BINFIN. Medicinal products containing finasteride (finasteride) and dutasteride (dutasteride): new measures to minimize the risk of suicidal thoughts

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration